Yisheng Jiankang Unveils AIGC Medical Product 'Aichao GPT' to Revolutionize Women's Health

Recently, at the roundtable forum titled “How Brands Can Reinvent Themselves Amid Homogeneous Competition” during the 2023 Jinmai Quality Awards Ceremony, Wang Qiangyu, Founder and CEO of Testing OneLife, revealed that the company is currently developing a substantively innovative AIGC medical product targeting the domestic women’s health market—“AiChao GPT” (AiChao Wen).

“Love Nest GPT” is an AI large model-based medical product that integrates foundational technologies from multidisciplinary expert teams in pathology, clinical practice, biological testing, the internet, and AI, while aggregating high-quality medical data. Functioning similarly to an AI gynecologist, this product allows female users to ask questions about gynecological issues anonymously, with all queries deleted immediately after responses are provided, ensuring that no user privacy data is retained on the platform.

This medical product will be a boon for women in China. Testing OneLife has always focused on the female endocrine system, redefining the field of internal anti-aging for women. The company has achieved a technological breakthrough in precise, at-home early screening of ovarian function using peripheral blood, and for the first time in the industry, it has provided a closed-loop health service for women’s internal anti-aging across the entire life cycle.

Testing OneLife’s AiChaoCe has been honored with the Taobao Tianxia Jinmai Quality Award, a recognition that fully affirms its innovative efforts in the field of women’s health. Furthermore, the launch of “AiChao GPT” (AiChao Wen) will provide female users with more comprehensive health support.

Testing OneLife, grounded in science and medicine, has introduced a “scientific approach to ovarian care” and provides comprehensive, lifecycle-wide health services to women. The company initially offers at-home testing kits, enabling female users to receive test results without leaving home, thereby saving time and conserving hospital medical resources.

However, the key challenge lies in making home-based testing precise and reliable. To address this, scientists at Testing OneLife have successfully developed precision micro-testing technology and an integrated device for capillary blood collection. With this device, users can complete precise, quantitative, and convenient capillary blood collection in just a few minutes, while ensuring sample safety and reliability, thereby enabling accurate detection of multiple indicators.

Data indicate that the test results from dried blood spots prepared using capillary blood, developed by Testing OneLife, are largely consistent with those from venous plasma, meeting medical standards. This precise micro-testing technology offers significant convenience to users and creates broad opportunities in the home-based testing market for women's health. Unlike other home-testing products, Testing OneLife’s blood sample information is richer, with more detectable indicators, while the development of an integrated device for capillary blood collection enhances user experience. This innovation is expected to drive a surge in the home-testing sector, providing health protection for more women.

In summary, Testing OneLife continues to innovate in the field of women’s health. Spearheaded by its AIGC-powered medical product, “AiChao GPT,” the company has opened up new market prospects and delivered a novel health experience to female users. This innovation is poised to have a profound impact on the women’s health sector in the years to come.